Polyinosinic-polycytidylic acid sodium

• CAT Number: I016843
• CAS Number: 42424-50-0
• Molecular Formula: (C₁₀H₁₃N₄O₈P)x.(C₉H₁₄N₃O₈P)x.xNa
• Purity: ≥95%

Polyinosinic-polycytidylic acid sodium (CAT: I016843), a synthetic analog of double-stranded RNA, functions as an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). It has multiple immunomodulatory effects and can be utilized as a vaccine adjuvant to enhance innate and adaptive immune responses. Additionally, Polyinosinic-polycytidylic acid sodium has been shown to induce apoptosis directly in cancer cells. In vitro, studies demonstrate that treatment with Polyinosinic-polycytidylic acid sodium reduces cell viability and induces apoptosis in various cancer cell lines. It also induces the expression of IFN-β, a key cytokine involved in antiviral and antitumor immune responses, through the activation of RIG-I and MDA-5. Moreover, Polyinosinic-polycytidylic acid sodium exhibits tumor growth inhibition in animal models. Proper preparation of Polyinosinic-polycytidylic acid sodium for injection involves solubilization and annealing of the double-stranded RNA.

Reference

[1]. Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119(8):2399-411.[2]. Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10(12):1219-23.[3]. Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24(6):996-1007.